Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.


Last reviewed on RxList: 12/12/2019
Quzyttir Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 12/12/2019

What Is Quzyttir?

Quzyttir (cetirizine hydrochloride injection) is a histamine-1 (H1) receptor antagonist used to treat acute hives (urticaria) in adults and children 6 months of age and older.

What Are Side Effects of Quzyttir?

Common side effects of Quzyttir include:

Dosage for Quzyttir

The recommended dose of Quzyttir for adults and adolescents 12 years of age and older is 10 mg. The recommended dose of Quzyttir for children 6 to 11 years is 5 mg or 10 mg. The recommended dose of Quzyttir for children 6 months to 5 years is 2.5 mg.

What Drugs, Substances, or Supplements Interact with Quzyttir?

Quzyttir may interact with other drugs. Tell your doctor all medications and supplements you use.

Quzyttir During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Quzyttir; it is unknown how it would affect a fetus. Quzyttir passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Quzyttir (cetirizine hydrochloride injection) for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Allergies can best be described as: See Answer
Quzyttir Professional Information


The following clinically significant adverse reaction is described elsewhere in the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Oral Cetirizine Hydrochloride

The following adverse reactions associated with the use of oral cetirizine hydrochloride were identified in clinical trials.

In clinical trials in patients 12 years and older the most common adverse reactions to oral cetirizine hydrochloride occurring with a 2% or greater incidence and greater than placebo were somnolence (14%), fatigue (6%), dry mouth (5%), pharyngitis (2%), and dizziness (2%). In clinical trials in children 6 to 11 years of age with oral cetirizine hydrochloride the most common adverse reactions occurring with a 2% or greater incidence and greater than placebo were headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting. Somnolence appeared to be dose related. Adverse reactions reported in placebo-controlled trials with oral cetirizine hydrochloride in pediatric patients 2 to 5 years were qualitatively similar in nature and generally similar in frequency to those reported in trials with children 6 to 11 years of age. In placebo-controlled trials of pediatric patients 6 to 24 months of age, the incidences of adverse experiences were similar in the oral cetirizine hydrochloride and placebo treatment groups in each trial. In a trial of 1 week duration in children 6 to 11 months of age patients who received oral cetirizine hydrochloride exhibited greater irritability/fussiness than patients on placebo. In a trial of 18 months duration in patients 12 months and older, insomnia occurred more frequently in patients who received oral cetirizine hydrochloride compared to patients who received placebo.


The safety data of QUZYTTIR was evaluated in a randomized, double-blind, single-dose, non-inferiority study comparing QUZYTTIR to intravenous diphenhydramine in 262 adults with acute urticaria.

The adverse reactions with QUZYTTIR occurred at an incidence of less than 1% and include: dyspepsia, feeling hot, dysgeusia, headache, paresthesia, presyncope, and hyperhidrosis.

An additional randomized, double-blind, single dose study was conducted in 33 adults which showed similar safety results.


Subject-rated sedation scores were assessed at baseline, 1 hr, and/or 2 hrs, and/or "Readiness for Discharge”. Sedation was rated on a 0 to 3 scale (0 = none, to 3 = severe) with lower sedation scores indicating less sedation. Subjects in the QUZYTTIR treatment group reported less sedation at all time points compared to subjects treated with diphenhydramine.

Read the entire FDA prescribing information for Quzyttir (Cetirizine Hydrochloride Injection)


Could I Be Allergic? Discover Your Allergy Triggers See Slideshow
Related Resources for Quzyttir

© Quzyttir Patient Information is supplied by Cerner Multum, Inc. and Quzyttir Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors